Pallavi S. Mishra‐Kalyani

Author

United States Food and Drug Administration ORCID

Also Known As

Mishra-Kalyani, Pallavi, Mishra-Kalyani, Pallavi S., P. Mishra-Kalyani, P.S. Mishra-Kalyani, Pallavi Mishra-Kalyani, Pallavi S Mishra-Kalyani, Pallavi S. Mishra-Kalyani, Pallavi S. Mishra‐Kalyani, Pallavi Shruti Mishra-Kalyani, Shan, Mingyang

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research Center for Devices and Radiological Health Clinical Research Institute Janssen (United States)

About

Pallavi S. Mishra‐Kalyani is an author at United States Food and Drug Administration specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	606
2	Health Sciences	9	9	529
3	Public Health	3	3	132
4	Biostatistics	3	3	132
5	Health Informatics	3	3	132

Pallavi S. Mishra‐Kalyani

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
FDA Approval Summary: Sotorasib for <i>KRAS G12C</i> -Mutated Metastatic NSCLC Erica C. Nakajima, Nicole Drezner, Xiaoxue Li, Clinical Cancer Research	2021	293
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond Lee H. Pai-Scherf, Gideon M. Blumenthal, Hongshan Li, The Oncologist	2017	286
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer Gideon M. Blumenthal, Yuexuan Gong, Kenneth L. Kehl, Annals of Oncology Time-to-treatment DiscontinuationMedicineClinical TrialsBronchial NeoplasmImmune Checkpoint Inhibitor	2019	151
Arm Pain in Youth Baseball Players Eric C. Makhni, Zachary S. Morrow, Timothy J. Luchetti, The American Journal of Sports Medicine	2014	107
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma Denise Casey, Suzanne Demko, A. K. Sinha, Clinical Cancer Research	2021	99
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or Fusions Janice Kim, Diana Bradford, Erin Larkins, Clinical Cancer Research Thyroid CancersCancer ManagementRadiation OncologyMolecular OncologyCancer Research	2021	99
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma Amy Barone, Maitreyee Hazarika, Marc R. Theoret, Clinical Cancer Research	2017	86
Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis. Oladimeji Akinboro, Jonathon Vallejo, Erica C. Nakajima, Journal of Clinical Oncology	2022	77
FDA Approval Summary: Selpercatinib for the Treatment of Advanced <i>RET</i> Fusion-Positive Solid Tumors Elizabeth S. Duke, Diana Bradford, Michelle Marcovitz, Clinical Cancer Research	2023	71
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice David J. Pinato, Thomas U. Marron, Pallavi S. Mishra‐Kalyani, European Journal of Cancer HepatologyLandmark Clinical TrialsMedicineImmunologyClinical Trials	2021	62

Page 1